Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 810
Estrogen Replacement Therapy and Fractures in Older Women
Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., Cummings, S. R., & and For The Study of Osteoporotic Fractures Research Group* (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00002 · Cited by 809
Serum vitamin D concentrations among elderly people in Europe
van der Wielen, R. P. J., de Groot, L. C. P. G. M., van Staveren, W. A., Löwik, M. R. H., van den Berg, H., Haller, J., & Moreiras, O. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91266-5 · Cited by 772
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Self-citationGenant, H. K., Grampp, S., Glüer, C. C., Faulkner, K. G., Jergas, M., Engelke, K., Hagiwara, S., & van Kuijk, C. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091002 · Cited by 610
Cited by
Items 801–900 of 1,002
Lindsay, R., Watts, N. B., Lange, J. L., Delmas, P. D., & Silverman, S. L. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2332-7 · Cited by 20
Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis
Miller, P. D. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50076-8 · Cited by 20
Osteoporose in der Unfallchirurgie: Prävalenz und Management
Vogel, T., Dobler, T., Bitterling, H., Biberthaler, P., Kanz, K., Pfeifer, K. J., Bartl, R., & Mutschler, W. (2005) · Der Unfallchirurg · doi:10.1007/s00113-005-0927-y · Cited by 20
Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy
Gold, D. T., Trinh, H., & Safi, W. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903035604 · Cited by 20
Miller, P. D. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253681 · Cited by 20
Ringe, J. D., van der Geest, S. A. P., & M??ller, G. (2006) · Drugs & Aging · doi:10.2165/00002512-200623070-00003 · Cited by 20
Bone densitometry, steroids and osteoporosis
Blake, G. M., & Fogelman, I. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200211000-00012 · Cited by 20
Pfeifer, R., Begerow, B., & Minne, H. W. (2004) · Cited by 20
Self-citationPrevención y tratamiento de la osteoporosis
Muñoz‐Torres, M., Alonso, G., & Raya, P. M. (2003) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(03)74488-x · Cited by 20
Corrao, G., Biffi, A., Porcu, G., Ronco, R., Adami, G., Alvaro, R., Bogini, R., Caputi, A. P., Cianferotti, L., Frediani, B., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1137671 · Cited by 19
Self-citationOsteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study
Keaveny, T. M., Adams, A. L., ORWOLL, E. S., Khosla, S., Siris, E. S., McClung, M. R., Bouxsein, M., Fatemi, S., Lee, D. C., & Kopperdahl, D. L. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae090 · Cited by 19
Migliorini, F., Maffulli, N., Colarossi, G., Filippelli, A., Memminger, M. K., & Conti, V. (2025) · European journal of medical research · doi:10.1186/s40001-025-02412-x · Cited by 19
Zambon, A., Baio, G., Mazzaglia, G., Merlino, L. G., & Corrao, G. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1530 · Cited by 19
Black, D. M., Bilezikian, J. P., Greenspan, S. L., Wüster, C., Muñoz‐Torres, M., Bone, H. G., Rosen, C. J., Andersen, H. S., & Hanley, D. A. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2098-3 · Cited by 19
Itoh, S., Sekino, Y., Shinomiya, K., & Takeda, S. (2012) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-012-0406-9 · Cited by 19
Herrero, S., & Picó, Y. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.02.053 · Cited by 19
Hill, Q. A., Grainger, J. D., Thachil, J. V., Provan, D., Evans, G., Garg, M. K., Bradbury, C. A., Bagot, C. N., Kanis, J. А., Compston, J. E., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15735 · Cited by 19
Catalano, A., Bellone, F., Santoro, D., Schwarz, P., Gaudio, A., Basile, G., Sottile, M. C., Stoian, S. A., Corica, F., & Morabito, N. (2021) · Nutrients · doi:10.3390/nu13061878 · Cited by 19
Iida, H., Sakai, Y., Seki, T., Watanabe, T., Wakao, N., Matsui, H., & Imagama, S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06264-z · Cited by 19
Kanis, J. А., McCloskey, E. V., Jönsson, B., Cooper, A., Ström, O., & Borgström, F. (2010) · Archives of Osteoporosis · doi:10.1007/s11657-010-0045-5 · Cited by 19
Clinical Use of Bone Turnover Markers to Monitor Pharmacologic Fracture Prevention Therapy
Schousboe, J. T., & Bauer, D. C. (2012) · Current Osteoporosis Reports · doi:10.1007/s11914-011-0091-y · Cited by 19
Clinical Management of Vertebral Compression Fractures
Miller, P. D. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.08.006 · Cited by 19
Kan, S.-L., Yuan, Z.-F., Chen, L., Sun, J.-C., Ning, G., & Feng, S. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-012937 · Cited by 19
Liu, H., Wang, H., Zhang, L., Sang, Y., Pu, F., Ren, J., & Qu, X. (2020) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2020.128630 · Cited by 19
Sugie-Oya, A., Takakura, A., Takao-Kawabata, R., Sano, H., Shimazu, Y., Isogai, Y., Yamaguchi, A., & Ishizuya, T. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0670-6 · Cited by 19
Iba, K., Takada, J., Hatakeyama, N., Ozasa, Y., Wada, T., & Yamashita, T. (2008) · Journal of Orthopaedic Science · doi:10.1007/s00776-008-1265-z · Cited by 19
Dimai, H. P., Pietschmann, P., Resch, H., Preisinger, E., Fahrleitner‐Pammer, A., Dobnig, H., & Klaushofer, K. (2009) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-009-0656-x · Cited by 19
Long-term Outcome of Weekly Bisphosphonates
Rizzoli, R. (2006) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000200249.12006.6e · Cited by 19
Parathyroid Hormone for the Treatment of Osteoporosis
McClung, M. R. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000146584.12831.c9 · Cited by 19
Boonen, S. (2007) · Bone · doi:10.1016/j.bone.2007.03.003 · Cited by 19
Sirola, J. P., Kr�ger, H., Sandini, L., Tuppurainen, M., Jurvelin, J. S., Saarikoski, S., & Honkanen, R. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-2069-3 · Cited by 19
Current controversies in bone densitometry
Bonnick, S. L. (2002) · Current Opinion in Rheumatology · doi:10.1097/00002281-200207000-00015 · Cited by 19
Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies
Silverman, S. L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9400-1 · Cited by 18
Bisphosphonate use after clinical fracture and risk of new fracture
Bergman, J., Nordström, A., & Nordström, P. (2018) · Osteoporosis International · doi:10.1007/s00198-017-4367-7 · Cited by 18
Díez‐Pérez, A. (2002) · Maturitas · doi:10.1016/s0378-5122(02)00145-7 · Cited by 18
Die Therapie der Osteoporose aus dem Blickwinkel einer auf Evidenz basierenden Medizin
Pfeifer, M. A., LEHMANN, R., & Minne, H. W. (2001) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/pl00002204 · Cited by 18
Self-citationClinical evaluation for osteoporosis
Becker, C. (2003) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00068-x · Cited by 18
Osteoporosis Treatment: When to Discontinue and When to Re-start
Adami, S., Idolazzi, L., Fracassi, E., Gatti, D., & Rossini, M. (2013) · Bone Research · doi:10.4248/br201304003 · Cited by 18
de Waure, C., Specchia, M. L., Cadeddu, C., Capizzi, S., Capri, S., Pietro, M. L. D., Veneziano, M. A., Gualano, M. R., Kheiraoui, F., Torre, G. L., et al. (2014) · BioMed Research International · doi:10.1155/2014/975927 · Cited by 18
Pharmacological treatment of osteoporosis for people over 70
Álvarez, M. J. M., & Díaz Curiel, M. (2007) · Aging Clinical and Experimental Research · doi:10.1007/bf03324697 · Cited by 18
Improved GI Tolerability with Monthly Ibandronate in Women Previously Using Weekly Bisphosphonates
Binkley, N., Martens, M. G., Silverman, S. L., Derman, R. J., Greenwald, M., Kohles, J. D., & Bachmann, G. A. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e31819ed0dd · Cited by 18
Prevention and Treatment of Osteoporosis in Primary Care Offices
Gill, J. M., & Hoffman, M. (2003) · Journal of Women s Health · doi:10.1089/154099903766651595 · Cited by 18
Bisphosphonates for Breast Cancer: Questions Answered, Questions Remaining
Layman, R. M., Olson, K. B., & Poznak, C. H. V. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.03.004 · Cited by 18
An Observational Study on the Adherence to Treatment Guidelines of Osteopenia
Buencamino, M. C. A., Sikon, A. L., Jain, A., & Thacker, H. L. (2009) · Journal of Women s Health · doi:10.1089/jwh.2008.0897 · Cited by 18
Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA
Sambrook, P. N., Cranney, A., & Adachi, J. D. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903512321 · Cited by 18
Osteodensitometry and ultrasound measurements of bone. Methods, indications, and efficacy
Kann, P. H. (2001) · Der Orthopäde · doi:10.1007/s001320170074 · Cited by 18
Combination/sequential therapy in osteoporosis
Lecart, M.-P., Bruyère, O., & Reginster, J. (2004) · Current Osteoporosis Reports · doi:10.1007/bf02686925 · Cited by 18
Self-citationHigh Rates of Imminent Subsequent Fracture After Femoral Neck Fracture in the Elderly
Bogoch, E. R., Marcano-Fernández, F. A., Schemitsch, E. H., Zhou, Q. X., Bzovsky, S., Bhandari, M., Schneider, P., Swiontkowski, M. F., Sprague, S., the FAITH Investigators, et al. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.22.00088 · Cited by 17
Gu, J., Wang, L., Lin, H. V., Chen, D., Tang, H., Jin, X., Xia, W., Hu, Y.-Q., Fu, W., He, J., et al. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.30 · Cited by 17
Healing of subtrochanteric atypical fractures after strontium ranelate treatment.
Negri, A. L., & Spivacow, F. R. (2012) · Europe PMC (PubMed Central) · Cited by 17
Kaštelan, D., Lozo, P., Stamenković, D., Miškić, B., Vlak, T., Kolak, Ž., Ahić, J. M., Altabas, V., Orlić, Ž. C., & Koršić, M. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-1039-1 · Cited by 17
Bisfosfonatbehandling av osteoporose og andre skjelettsykdommer
Syversen, U., & Halse, J. (2011) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.09.0470 · Cited by 17
Advances in osteoporosis from 1970 to 2018
Gallagher, J. C. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001263 · Cited by 17
Mehl, B., Delling, G., Schlindwein, I., Heilmann, P., Voia, C., Ziegler, R., Nawroth, P. P., & Kasperk, C. H. (2002) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-002-1199-8 · Cited by 17
Recombinant Parathyroid Hormone in the Management of Osteoporosis
Compston, J. E. (2005) · Calcified Tissue International · doi:10.1007/s00223-005-0012-0 · Cited by 17
Kingkaew, P., Maleewong, U., Ngarmukos, C., & Teerawattananon, Y. (2012) · Value in Health · doi:10.1016/j.jval.2011.11.015 · Cited by 17
Wasserfallen, J., Krieg, M.-A., Greiner, R.-A., & Lamy, O. (2008) · Journal of Medical Economics · doi:10.3111/13696990802332770 · Cited by 17
Mulgund, M., BEATTIE, K. A., Wong, A. K. O., Παπαϊωάννου, Α., & Adachi, J. D. (2009) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x09339551 · Cited by 17
Bisphosphonates in osteoporosis
Fleisch, H. A. (2005) · Springer eBooks · doi:10.1007/3-540-27376-x_8 · Cited by 17
Watts, N. B. (2001) · Osteoporosis International · doi:10.1007/pl00014037 · Cited by 17
Recker, R. R., Ste‐Marie, L., Langdahl, B. L., Masanauskaite, D., Ethgen, D. J., & Delmas, P. D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.10.006 · Cited by 17
Self-citationAdvances in osteoporosis therapy. 2003 update of practical guidelines.
Khan, A. A. (2003) · PubMed · Cited by 17
Risedronate: a new oral bisphosphonate
Umland, E. T., & Boyce, E. G. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80116-8 · Cited by 17
Monitoring treatment for osteoporosis by using bone densitometry
Blake, G. M., & Fogelman, I. (2001) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2001.23528 · Cited by 17
Tankó, L. B., & Christiansen, C. (2007) · Elsevier eBooks · doi:10.1016/b978-012369443-0/50036-3 · Cited by 17
MANAGEMENT OF PRIMARY OSTEOPOROSIS
Body, J. J. (2002) · Acta Clinica Belgica · doi:10.1179/acb.2002.054 · Cited by 17
Oral Therapeutics Post Menopausal Osteoporosis
Schroeder, R., Staszkiewicz, J., O’Quin, C. C., Carroll, B., Doan, N., Patel, S., Ahmadzadeh, S., Kallurkar, A., Viswanath, O., Varrassi, G., et al. (2023) · Cureus · doi:10.7759/cureus.42870 · Cited by 16
Schini, M., Vilaça, T., Vittinghoff, E., Lui, L., Ewing, S. K., Thompson, A. R., Bauer, D. C., Bouxsein, M., Black, D. M., & Eastell, R. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae040 · Cited by 16
Self-citationHenríquez, M. S., & Romero, M. J. G. D. T. (2009) · Revista Clínica Española · doi:10.1016/s0014-2565(09)70355-8 · Cited by 16
Risk of Fracture and the Concomitant Use of Bisphosphonates With Osteoporosis-Inducing Medications
Nyandege, A. N., Slattum, P. W., & Harpe, S. E. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015569594 · Cited by 16
Zoledronic Acid in the Treatment of Early-Stage Breast Cancer: Is There a Final Verdict?
Gnant, M. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0209-5 · Cited by 16
Al-Toma, A. A., Herman, A., Lems, W. F., & Mulder, C. J. J. (2022) · Nutrients · doi:10.3390/nu14214554 · Cited by 16
Sunyecz, J. A. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2496 · Cited by 16
Utilización de fármacos para la osteoporosis
Erviti, J. (2003) · Anales del Sistema Sanitario de Navarra · doi:10.4321/s1137-66272003000600010 · Cited by 16
Boonen, S., Kay, R., Cooper, C. C., Haentjens, P., Vanderschueren, D., Callewaert, F., Milisen, K., & Ferrari, S. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02206.x · Cited by 16
Amagase, K., Inaba, A., Senta, T., Ishikawa, Y., Nukui, K., Murakami, T., & Takeuchi, K. (2011) · PubMed · Cited by 16
Management of Osteoporosis in Older People
Inderjeeth, C. A., & Poland, K. E. (2010) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2010.tb00545.x · Cited by 16
Response of Postpoliomyelitis Patients to Bisphosphonate Treatment
Alvarez, A., Kremer, R. B., Weiss, D. R., Benedetti, A., Haziza, M., & Trojan, D. A. (2010) · PM&R · doi:10.1016/j.pmrj.2010.08.009 · Cited by 16
Changes in first hip fracture rates in British Columbia Canada, 1990–2004
Lefaivre, K. A., Levy, A. R., Sobolev, B., Cheng, S. Y., Kuramoto, L., & Guy, P. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1488-7 · Cited by 16
Bisphosphonates for Postmenopausal Osteoporosis
Giusti, A., & Papapoulos, S. E. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch71 · Cited by 16
Prevention of vertebral fractures by strontium ranelate in postmenopausal women with osteoporosis
Compston, J. E. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1760-9 · Cited by 16
İlter, E., Karalök, H., Tüfekçi, E. C., & Batur, O. (2006) · Climacteric · doi:10.1080/13697130600652180 · Cited by 16
Management of Postmenopausal Osteoporosis: Defining the Role of Raloxifene
Wellington, K., & Plosker, G. L. (2003) · Disease Management & Health Outcomes · doi:10.2165/00115677-200311100-00006 · Cited by 16
Intermittent Bisphosphonate Therapy in Postmenopausal Osteoporosis: Progress to Date
Reginster, J., Malaise, O., Neuprez, A., Jouret, V.-E., & Close, P. (2007) · Drugs & Aging · doi:10.2165/00002512-200724050-00001 · Cited by 16
Self-citationProtelos: Nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis
Adami, S. (2006) · Bone · doi:10.1016/j.bone.2005.08.028 · Cited by 16
Efficacy and Tolerability of Cyclical Intravenous Pamidronate in Patients with Low Bone Mass
Younes, H., Farhat, G. N., & Fuleihan, G. E. (2002) · Journal of Clinical Densitometry · doi:10.1385/jcd:5:2:143 · Cited by 16
Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities
Reginster, J. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01292.x · Cited by 16
Self-citationZegels, B., Eastell, R., Russell, R. G. G., Ethgen, D. J., Roumagnac, I., Collette, J., & Reginster, J. (2001) · Bone · doi:10.1016/s8756-3282(00)00410-5 · Cited by 16
Self-citationThe use of bisphosphonates in women: when to use and when to stop
Gatti, D., Adami, S., Viapiana, O., & Rossini, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1087506 · Cited by 15
Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients
Nguyen, P. V.-Q., Bouin, M., & Ste‐Marie, L. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05498-7 · Cited by 15
Jeon, I., Park, S. B., Moon, B. J., Choi, M., Kuh, S. U., & Kim, J. (2024) · Neurospine · doi:10.14245/ns.2347256.628 · Cited by 15
Osteoporosis treatment: why ibandronic acid?
Rossini, M., Orsolini, G., Adami, S., Kunnathully, V., & Gatti, D. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.795949 · Cited by 15
Drug Injury in the Upper Gastrointestinal Tract: Effects of Alendronate
Khapra, A., & Rose, S. (2006) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2006.01.002 · Cited by 15
Adherence of academic geriatric practitioners to osteoporosis screening guidelines
McNally, D., Kenny, R. A., & Smith, J. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0215-x · Cited by 15
Ito, M., Tobinai, M., Yoshida, S., Hashimoto, J., & Nakamura, T. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0723-x · Cited by 15
Primary osteoporosis in men: an unmet medical need
Mendoza, F. A., Roux, M. L., & Ahmed, I. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.10.003 · Cited by 15
Takakuwa, M., & Iwamoto, J. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00200 · Cited by 15
Identification and treatment of osteoporosis in fractures
McLellan, A. R. (2003) · Current Rheumatology Reports · doi:10.1007/s11926-003-0084-7 · Cited by 15
Bisphosphonates in phenytoin-induced bone disorder
Khanna, S., Pillai, K. K., & Vohora, D. (2010) · Bone · doi:10.1016/j.bone.2010.10.172 · Cited by 15
Metadata
- Authors
- Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., & Eastell, R.
- Affiliations
- University of Liège (BE)
- The University of Sydney (AU)
- Hôpital Cochin (FR)
- University of Florence (IT)
- Procter & Gamble (United States) (US)
- University of Sheffield (GB)
- Venue
- Osteoporosis International
- Published
- 2000-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 83-91
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W1526826623
- Cited by
- 1,580
- References
- 29
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 25 · 2022: 26 · 2021: 31 · 2020: 38 · 2019: 30 · 2018: 36 · 2017: 27 · 2016: 44 · 2015: 50 · 2014: 47 · 2013: 69 · 2012: 66
- FWCI
- 78.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- risedronate, postmenopausal osteoporosis, vertebral fractures, fracture prevention, bisphosphonates, bone mineral density, non-vertebral fractures, calcium and vitamin D supplementation, gastrointestinal adverse effects, drug safety
- MeSH terms
- Risedronic Acid, Aged, Aged, 80 and over, Algorithms, Australia, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Middle Aged, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.